Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Pz-cel

Cell therapy · Cell replacement · developed by Abeona Therapeutics

Phase 4 Most advanced trial

ABEO Developer

1 Registered trials

What is Pz-cel?

Pz-cel is a cell therapy applied surgically to wounds in patients with epidermolysis bullosa, including recessive dystrophic epidermolysis bullosa (RDEB) and dystrophic epidermolysis bullosa (DEB).

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Cell therapy
Mechanism: Cell replacement
Therapy area: Dermatology
Developer: Abeona Therapeutics, Inc (ABEO)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 4

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07717736	Phase 4	Epidermolysis Bullosa (EB)	Not yet recruiting	ABEO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Dystrophic Epidermolysis Bullosa (DEB)Epidermolysis Bullosa (EB)Recessive Dystrophic Epidermolysis Bullosa (RDEB)

More from Abeona Therapeutics

ABO-101 N/A EB-101 Phase 3 LZRSE-Col7A1 Phase 1/2 MSI-78 Phase 3 rAAV9.CMV.hNAGLU Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ABEO page.

Follow ABEO, the company behind Pz-cel

See ABEO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABEO catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z